|About OncoVista: Overview|
Introducing OncoVista Innovative Therapies.
OncoVista Innovative Therapies, Inc. (OTCBB: OVIT) is a high-growth theragnostic (the fusion of therapeutic and diagnostic medicine for individual patients) company that identifies specific biomarkers in the bloodstream carried by CTC’s to detect metastatic tumors. This technology allows an oncologist the unique ability to develop personalized, efficacious cancer treatments, thereby evaluating cancer therapeutic efficacy that can dramatically improve a patient’s chance of survival. OncoVista also produces innovative drug discovery, registration strategies and emerging technologies allowing it to bring to market less toxic and highly effective anti-cancer drugs.
Prior to establishing OncoVista, Chief Executive Officer Dr. Alexander Weis was co-founder of Ilex Oncology Inc., a cancer-drug company. Genzyme Corp. of Massachusetts acquired the San Antonio cancer-drug company for a reported $1 billion in 2004.